Theriva Biologics (Theriva Biologics) Change In Working Capital : $2.31 Mil (TTM As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Theriva Biologics Change In Working Capital?

Theriva Biologics's change in working capital for the quarter that ended in Dec. 2023 was $0.47 Mil.

Theriva Biologics's change in working capital for the fiscal year that ended in Dec. 2023 was $2.31 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Theriva Biologics Change In Working Capital Historical Data

The historical data trend for Theriva Biologics's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theriva Biologics Change In Working Capital Chart

Theriva Biologics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

0.86

-2.78

0.71

-0.81

2.31

Theriva Biologics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-0.90	-1.18	0.84	2.17	0.47

Theriva Biologics Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.31 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Theriva Biologics Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Theriva Biologics's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Theriva Biologics (Theriva Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theriva Biologics Inc (AMEX:TOVX) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

SFY:Germany

Address

9605 Medical Center Drive, Suite 270, Rockville, MD, USA, 20850

Website

https://www.therivabio.com

Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11, leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.

Executives

Steven A Shallcross	director, officer: CEO and CFO	C/O ELYS GAME TECHNOLOGY CORP., 130 ADELAIDE STREET WEST, SUITE 701, TORONTO A6 M5H2K4
Francis Tufaro	officer: Chief Operating Officer	9605 MEDICAL CENTER DRIVE SUITE 270, ROCKVILLE MD 20850
John J Monahan	director
Scott Tarriff	director	28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Randal J Kirk	10 percent owner	1881 GROVE AVENUE, RADFORD VA 24141
Joseph A. Sliman	officer: CHIEF MEDICAL OFFICER	9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE MD 20850
Jeffrey Scott Riley	director	C/O ADEONA PHARMACEUTICALS, INC, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
Intrexon Corp	10 percent owner	20374 SENECA MEADOWS PARKWAY, GERMANTOWN MD 20876
Charles Evan Ballantyne	officer: CHIEF FINANCIAL OFFICER	27 HEARTHSTONE ROAD, HOPKINTON MA 01748
Nelson K. Stacks	director	C/O ADEONA PHARMACEUTICALS, INC., 3985 RESEARCH PARK DRIVE, SUITE 200, ANN ARBOR MI 48108
Lyon Lyman Max Jr	director, officer: CEO & President	C/O ADEONA PHARMACEUTICALS, 3930 VARSITY DRIVE, ANN ARBOR MI 48108
David A. Newsome	officer: Chief Scientific Officer	3930 VARSITY DRIVE, C/O PIPEX PHARMACEUTICALS, INC., ANN ARBOR MI 48108
James S Kuo	director	509 MADISON AVE 14TH FL, NEW YORK NY 10022
Daniel J Dorman	director
Wayne George Holman	10 percent owner	430 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022